R&D News | pharmaphorum

News

GSK goes all-in on CureVac’s mRNA vaccines

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and

News

Advantage J&J in multiple myeloma CAR-T tussle with BMS

Johnson & Johnson and partner Legend Biotech are celebrating a big win in their efforts to expand the use of CAR-T therapy Carvykti for multiple myeloma, after showing a survival benefi

News

Radionetics Oncology's chief executive Paul Grayson

Lilly builds in radiopharma with $140m Radionetics deal

Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outr

News

NeuroSense says ALS drug extends survival

NeuroSense Therapeutics is currently facing de-listing from the Nasdaq, so encouraging data from a phase 2b trial of its PrimeC drug candidate for amyotrophic lateral sclerosis (ALS) comes

News

BMS hands back rights to cancer ADC licensed from Eisai

Bristol-Myers Squibb has ended a $3.1 billion strategic collaboration with Eisai focusing on antibody-drug conjugates (ADCs) and returned rights to the lead drug in the alliance.

News

J&J adds another string to nipocalimab bow with gMG data

Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drug

GSK goes all-in on CureVac’s mRNA vaccines

Advantage J&J in multiple myeloma CAR-T tussle with BMS

Lilly builds in radiopharma with $140m Radionetics deal

NeuroSense says ALS drug extends survival

BMS hands back rights to cancer ADC licensed from Eisai

J&J adds another string to nipocalimab bow with gMG data

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks